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Abstract
Dilated cardiomyopathy (DCM) is a myocardium disease characterized by left 
ventricular dilation and systolic dysfunction. Genetic susceptibility contributes 
significantly to the disease progression in familial DCM. Mutations in more than 
fifty different genes have been identified to cause DCM, accounting for up to 50% 
of familial DCM cases. Elucidation of genetic basis for the remaining familial DCM 
probands promises to substantially increase the efficiency of genetic testing for 
early disease diagnosis and intervention. Dissecting genetic pathways linked to 
DCM and related pathogenic mechanisms can provide valuable insights into the 
understanding of disease pathophysiology that can be leveraged for development 
of genotype-targeted therapeutic strategy. Here, we review genetic variants, with 
a focus on affected genes most commonly implicated in DCM, and highlight their 
underlying pathophysiological mechanisms of action. We discuss recent progress 
on gene-based therapeutic strategy which holds the opportunities to implement 
individualized medicine and ultimately to improve patient outcome in the future.
Keywords: dilated cardiomyopathy, genetic determinant, genetic testing,  
gene therapy, pathophysiology
1. Introduction
Heart failure afflicts about 26 million patients worldwide. The estimated economic 
burden related to heart failure is 120 billion US dollars [1]. Dilated cardiomyopathy 
(DCM), referred to a group of heart muscle disorders characterized by heart chamber 
dilation and systolic dysfunction, is a common cause of heart failure. DCM is the most 
common form of non-ischemic cardiomyopathy and the most common indication in 
patients who need heart transplantation [2, 3]. In the pediatric, nearly 50% of patients 
dying suddenly or undergoing cardiac transplantation are affected by cardiomyopa-
thy, predominantly by DCM [4]. In the young, DCM is the most frequent cause of 
heart failure [5]. In the adult, it is the second most common cause of heart failure 
(after the coronary heart disease), underlying about one third of all heart failure cases 
[1]. While the true prevalence for DCM in general population is not fully defined 
yet due to lack of well-designed large-scale population based studies, its estimated 
prevalence ranges from 1 in 2500 to 1 in 250 people [6]. The annual incidence of DCM 
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is approximately 7 cases per 10,000 individuals, and males are about 3 times more 
frequently affected than females [2, 7, 8].
Classically, DCM is defined based on two major criteria: 1) left LV fractional 
shortening <25% (> 2 standard deviations [SD]) and/or LV ejection fraction <45% 
(>2 SD); and 2) LV end-diastolic diameter greater than 117% of the predicated 
value corrected for age and body surface area. DCM is diagnosed when any other 
known cause of myocardial diseases are excluded [9]. The updated definitions of 
DCM are left ventricular or biventricular systolic dysfunction and dilatation that 
are not explained by abnormal loading conditions or coronary artery disease [10].
DCM is caused by a variety of etiologies, including acquired, genetic and/or 
mixed origins. Acquired risk factors such as infection, myocarditis, drug toxin, 
autoimmune response, excess alcohol consumption and metabolic disorders are 
recognized to cause DCM. Primary DCM results when all these acquired factors are 
exclude, which can be either idiopathic or familial. Familial DCM (FDC) is clas-
sified when two or more family members are diagnosed in first-degree relatives. 
The prevalence of familial DCM differs in different patient cohorts, estimated to 
range from 20–50% of all DCM cases. The remaining DCM cases are thus classi-
fied as idiopathic [6, 11]. However, the frequency of familial DCM is believed to 
be underestimated, due to the limitation of large pedigree and family’s availability 
for diagnostic screening. Genetic factors which predispose to DCM have been 
increasingly recognized. Since the discovery of the first disease causative gene to 
cardiomyopathy [12], to date, more than 50 genes have been identified to associate 
with DCM and the number is still increasing. Genetic mutations in all these genes 
combined can explain about 40–50% of familial DCM cases, underpinning the 
genetic determinant of this disease [6]. The familial DCM appears to be inherited as 
a monogenic trait and is mainly transmitted in an autosomal dominant inheritance 
pattern, manifesting incomplete, age-related penetrance and variable expression. 
Other patterns such as autosomal recessive, X-linked and mitochondrial inheritance 
also occurs in a small portion of the familial DCM cases [6, 13].
Current management of DCM is mainly focused on treating patients with 
symptoms following the standard guidelines, similar to treating other forms of 
heart failure with reduced ejection fraction (EF). The guideline driven therapies 
mostly adapt a “one-size-fits-all” approach that uses β-adrenergic blockers, 
angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers to 
improve cardiac function and symptom by reducing congestion and management 
of arrhythmia [14, 15]. Recently, several new additions of armamentarium are 
also implemented in the treatment options [16–18]. Despite of advances in these 
treatment protocols, DCM remains one of the major reasons for patients needed 
for heart transplantation, and the morbidity and mortality rate of DCM still 
remains unacceptably high. Thus, the current management of DCM with the “one-
size-fits-all” strategy is challenged. More novel and effective and individualized 
treatment options are desirable.
Considering the genetic determinant of DCM, and up to 50% of familial DCM 
patients have a genetic origin, genotype-targeted therapies, by directly targeting at 
the specific gene mutations, have emerged as promising strategies toward develop-
ment of more effective and individualized treatment. In this chapter, we firstly 
review definitive genes linked to DCM and classify them based on their intracellular 
localization (Figure 1), with a major focus on genes most commonly implicated 
in DCM, and highlight their underlying pathophysiological mechanism of action 
if known (Table 1). Next, we discuss progress and challenges on the emerging 
genotype-based therapeutic strategies for effective and individualized medicine 
explored in the treatment of DCM (Table 2), which hold the opportunities to 
ultimately improve patient outcome in the future.
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Figure 1. 
Subcellular localization of the protein encoded by dilated cardiomyopathy disease genes. The graphic shows 
schematic representations and approximate intracellular localization of the encoded proteins by genes strongly 
implicated in dilated cardiomyopathy disease.
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2. Genetic causes of familial DCM
Extensive studies on genetic basis of DCM underscored profound hetero-
geneous nature of DCM disease. DCM variants mutate genes encoding a broad 
spectrum of proteins with distinct functions and intracellular localization have 
been identified (Figure 1 and Table 1). For example, mutations in genes encoding 
sarcomere protein involving in mechanosensing and force transmission, encod-
ing nuclear envelope proteins required for the protection of biochemical forces, 
encoding desmosomal proteins required for maintaining the structural integrity 
of desomosome, encoding ion channels and molecules involving in calcium 
handling, encoding chaperone proteins, transcription factors and RNA-binding 
proteins have all been identified to cause DCM. Specific variants in these genes 
may alter various signaling pathways and cellular structures in cardiomyocyte that 
can disrupt the mechanism of cardiac muscle contraction and function, leading to 
common phenotypes of DCM.
2.1 Sarcomere genes
Sarcomere is the basic contractile unit mainly composed of thin and thick fila-
ments. Mutations in sarcomere genes are one of the most important causes of DCM, 
which have been identified in about one third of DCM [19–21]. In addition to cause 
DCM, mutations in sarcomere genes often lead to overlapping phenotypes of hyper-
trophic cardiomyopathy (HCM), another major genetic type of cardiomyopathy 
characterized by ventricular wall thickness and diastolic dysfunction. Genes with 























































Examples of gene-targeted therapeutic strategies.
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clinical linkage data and confirmative data from animal models, include ACTC1, 
MYH7, TNNT2, TNNC1, TRM1,TTN. Among which, TTN, MYH7 and TTNT2 
are most commonly implicated in DCM, accounting for about 25%, 5% and 3% of 
familial DCM, respectively.
TTN gene encodes the titin, the largest known protein in human, consisting of 
364 exons and about 35,000 amino acids that spans about a half of the sarcomere. 
It has long been recognized as a sarcomere scaffolding protein that serves as a blue 
print for sarcomerogenesis and myofibrillar assembly. In addition, titin also serves 
as a molecular spring that provides passive tension to regulate sarcomere contrac-
tion. With the advent of next-generation sequencing, human genetic analysis had 
revealed that TTN-truncating variants (TTNtvs) represent the most prevalent gene 
mutations in DCM patients, accounting for up to 25% of familial DCM cases [19]. 
Notebly, TTNtvs are also found in about 1% of general population [22, 23]. While 
not all of these healthy individuals with the TTNtvs are expected to develop DCM, 
they showed significantly increased left ventricular volumes and mild reduction of 
contractility [23]. Initially, it was hypothesized that TTNtvs caused DCM through 
a dominant negative mechanism [24]. This hypothesis is compromised by that 
truncated titin peptides were not detected from DCM hearts that harbored TTNtvs. 
Instead, there is evidence to support that premature truncations in the TTN tran-
scripts trigger nonsense-mediated decay in rat models with TTNtvs [23]. Together 
with recently cumulative data derived from studies in human induced pluripotent 
stem cell-derived cardiomyocytes (iPSC-CMs) and human cardiac tissues, the 
hypothesis of haploinsufficiency mechanisms is now more widely recognized [25].
MYH7 encodes the beta isoform of myosin heavy chain (MHC-β) that is 
predominantly expressed in the heart. MHC-β is a major component of the thick 
filament responsible for hydrolyzing ATP to produce force for cardiac muscle con-
traction. The Arg403Gln missense mutation of MYH7 was first identified to cause 
HCM back to 1990 [12]. Since then, many MYH7 variants were identified to associ-
ate with both HCM and DCM, accounting for approximately 40% of HCM and 
5% of DCM cases, respectively. The definitive mechanisms underlying how MYH7 
mutations cause different types of cardiomyopathies remain to be elusive. Clinically, 
HCM is often characterized by hypercontractility. In contrast, DCM is character-
ized by hypocontractility. Mutations in myosin head domain consume more energy, 
leading to hypercontractility. One observation is that the MYH7 variants associ-
ated with HCM are located more in the region encoding the myosin head domain, 
while MYH7 mutations causal to DCM appear to disperse across the entire gene. 
The Arg403Gln variant causal to HCM, for example, increased energy usage due to 
impaired catalytic cycle of ATP hydrolysis, resulting in increased contractility [26]. 
In contrast, mutations associated with DCM showed an increased tension cost, with 
more energy consumption, have reduced force-generating capacity, thus causes a 
hypocontractility, leading to DCM [27, 28]. For example, the ASN1918LYS variant, 
causal to DCM, is located to the coiled-coil rod region, which is hypothesized to 
impair the incorporation of myosin into the myofilaments.
TNNT2 encodes the cardiac muscle isoform of troponin T (cTnT). cTnT is one 
of the major tropomyosin-binding subunits of troponin on the thin filament that 
regulates cardiac muscle contraction. TNNT2 variants are thought to account for 
approximately 5% of HCM, up to 3% of DCM, and a small fraction of arrhythmo-
genic cardiomyopathy (ACM). Many mutations in TNNT2 causing DCM are located 
in both the middle and C-terminal regions of cTnT. These mutations mostly impair 
the cTnT’s interaction with the thin filament regulatory system, myofilament 
calcium sensitivity, and/or the myosin ATPase activity, thus cause DCM.
TPM1 encodes the alpha tropomyosin chain protein that belongs to the tropo-
myosin family of highly conserved thin filament proteins. In association with the 
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troponin complex, tropomyosin mostly participates in the calcium regulation of 
cardiac muscle contraction and interaction of actin and myosin. Mutations in TPM1 
cause both HCM and DCM phenotypes [29, 30], accounting for about 5% of HCM 
and 1% of DCM cases, respectively. Functional characterization of TPM1 mutations 
associated with both cardiomyopathies has led to a better understanding of the 
primary effects and consequence triggered by mutations in the long-range commu-
nication of the thin filament and specific phenotypes [31].
2.2 Nucleus and nuclear envelope genes
Mutations in gene encoding nucleus or nuclear envelope localized proteins that 
definitively link to DCM such as LMNA, EMD and RBM20 were reported. LMNA is 
the second most common gene implicated in DCM, and LMNA variants account for 
about 6–10% of genetic DCM [32, 33]. LMNA encodes the nuclear envelope localized 
lamins A and C resulted from differential splicing at the 3′ end. Both lamins A and C 
are intermediate filament structural proteins, playing major roles in supporting cells 
with stability and strength. LMNA mutations linked to DCM can be both missense 
and frameshift across the coding region. Both dominant negative and haploinsuffi-
ciency mechanisms were proposed for LMNA mutations caused DCM. Beyond their 
roles as structural proteins, both lamins A and C involve in many different cellular 
process including regulation of gene expression, mechanosensing and nuclear to 
cytoplasmic transport. Functional study in animal models revealed that ERK1/2, 
JNK and p38 kinase pathways were drastically activated in LMNA-associated DCM. 
By targeting to the p38 kinase pathway through using a specific p38 kinase inhibitor 
ARRY-371797, Muchir and colleagues showed that LV dilation and deterioration of 
EF were effectively blocked, and LMNA-related severe biomechanical defects were 
significantly rescued in neonatal rat ventricular myocytes [34, 35]. Based on their 
encouraging and other related data, a clinical trial to study the protective effect of 
ARRY-371797 on patients with symptomatic DCM due to LMNA gene mutations was 
initiated (NCT03439514). This represents one of the first clinical trials involving 
genotype-specific therapy particularly for DCM.
The RNA binding motif protein 20 (RBM20) gene encodes a nucleus localized 
RNA-binding protein. RBM20 protein mostly functions as a regulator of post-tran-
scriptional splicing of a subset of genes involved in cardiomyopathy, ion-homeo-
stasis, and sarcomere biology [36]. RBM20 is predominantly expressed in skeletal 
and cardiac muscles. Loss of function mutations in the RBM20 were firstly linked 
to familial DCM and account for 2–5% of DCM cases [37, 38]. Of the many targets 
regulated by RBM20, aberrant splicing of TTN is believed to be the main determi-
nant of RBM20 mutations caused DCM. Calcium/calmodulin-dependent kinase 
II delta (CAMK2D) is another pivotal cardiac gene transcriptionally regulated by 
RBM20. A recent study showed that RBM20 mutations carriers also had increased 
risk of malignant ventricular arrhythmias and sudden cardiac death (SCD), likely 
resultant from disturbed Ca2+ handling and arrhythmic Ca2+ cycling [39].
2.3 Cytoskeletal protein coding genes
Other genes such as DES, DMD and FLNC that encode components of cytoskel-
eton localized proteins are also identified to link to DCM pathogenesis. Pathogenic 
mutations in these genes causing DCM often accompany with additional pheno-
types, most notably skeletal myopathy. DES encodes desmin, a muscle-specific 
component of the intermediate filament presented at the Z-disk and intercalated 
discs that integrates sarcolemma, Z-disk and nuclear membrane to maintain the 
structural and functional integrity of sarcomeric contractile apparatus [40]. 
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Mutations in DES have been associated with a spectrum of cardiomyopathies, 
mostly notably DCM, in about 1–2% of cases [41]. Overlapping phenotypes of DES 
mutations including arrhythmia, cardiac conduction diseases, and skeletal myopa-
thy and smooth muscle defects are frequently observed.
Mutations in the gene encoding dystrophin (DMD) cause severe muscle weak-
ness and DCM in Duchenne muscular dystrophy (DMD). Because the DMD gene 
is located in the short arm of X chromosome, pathogenic mutations causing DMD 
mostly affect boys. The frequency of DMD caused muscular dystrophy and DCM is 
rare, with an estimated incidence 1 in 3500 male births worldwide [42]. Dystrophin 
protein is a key component of dystrophin-glycoprotein complex and plays a critical 
role in maintaining the structural integrity of sarcolemma during repeated cycles 
of muscle contraction and relaxation [43]. Mutations in DMD result in loss of the 
dystrophin protein expression that causes primary muscular dystrophy in males 
presenting with progressive muscle wasting at early childhood. Subsequently, 
cardiac dysfunction is involved and more than 90% of affected individuals manifest 
DCM and patient often died of cardiac and respiratory muscle failure [44].
2.4 Z-disk gene
The Z-disk is an anchoring plane for the actin (thin) filaments to attach and 
stabilize in the sarcomere. Mutations in many Z-disk-associated proteins coding 
genes result in cardiac disorders. BAG3 encodes a highly conserved, Z-disk localized 
co-chaperone protein that is predominantly expressed in heart and skeletal muscle. 
BAG3 binds to the ATPase domain of the heat shock protein (Hsp) 70 and exerts 
multiple functions in regulating apoptosis, preserving the integrity of sarcomere, 
mediating unfolded protein response and autophagy. BAG3 variants linked to 
DCM were firstly reported by two independent genome-wide association studies 
(GWASs). Later on, BAG3 mutations were identified in 2–7% of DCM cases [45–47]. 
Genotype–phenotype correlation study revealed that DCM attributed by BAG3 
mutations is characterized by high penetrance in carriers more than 40 years of age. 
Patients with BAG3 mutations are at a higher risk of developing a more severe and 
progressive heart failure compared with patients without BAG3 mutations [46]. The 
level of BAG3 protein was reduced by about a half in both animal models of heart 
failure and DCM patients as well. Based on the evidence that truncation or deletion 
mutations in BAG3 are associated with BAG3 haploinsufficiency which co-segregates 
with affected DCM family members, it was proposed that the decreased levels of 
BAG3 protein is the cause of DCM. BAG3 is also an independent heart failure risk 
factors associated with subclinical LV dysfunction. Thus, cumulative data support 
that BAG3 as a bona-fide disease susceptibility gene for DCM [48].
2.5 Ion channel gene
Mutations in the ion channel coding gene SCN5A are identified to cause DCM 
with strong supporting evidence. SCN5A encodes the sodium channel Nav1.5 that 
is mainly expressed in the cardiac muscle [49]. Mutations in SCN5A are associated 
primarily with conduction disorder, arrhythmia and DCM. Incidence of pathogenic 
SCN5A variants is estimated to be 2–4% in all DCM cases [50]. Missense mutations 
such as R222Q variant located in a voltage-sensing domain exert activating effects 
on sodium channel function and were thought to cause DCM. While guideline-
based heart failure therapies have moderate effect, drugs that have sodium channel-
blocking properties such as amiodarone or flecainide could substantially reduce 
DCM phenotype in patients with R222Q carriers [51]. Moreover, a recent report 
showed that quinidine treatment of a DCM patient with R222Q mutation achieved 
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a rapid and significant reduction of ventricular tachyarrhythmia and an improve-
ment in the myocardial function [52]. These interesting genotype–phenotype 
association studies thus provide another successful example of elucidation of the 
genetic basis of familial DCM which can lead to effective genotype-tailored thera-
peutic strategy.
2.6 Other DCM genes
PLN encodes phosphlamban, a transmembrane protein localized to the sar-
coplasmic reticulum. Mutations in PLN cause variable DCM phenotype, with 
underlying mechanisms proposed through inhibiting the sarcoplasmic reticulum 
Ca2 + -ATPase (SERCA2a) [53]. While founder mutation R14del mutation in PLN is 
associated with severe phenotype with high risk for lethal ventricular arrhythmias 
and end-stage heart failure in the European [54], a milder phenotype had been 
reported from others [55], suggesting that genetic background might have a big 
impact on modifying the disease progression associated with PLN mutations caused 
DCM.
Mutations in genes other encoding the sarcoglycans (α, β, γ, δ) were also 
identified to cause DCM. The sarcoglycans are transmembrane proteins mainly 
expressed in heart and skeletal muscle that interact with dystrophin. α-, β-, γ-, 
and δ-sarcoglycans form the sarcoglycan complex that is key components of the 
dystrophin-associated glycoprotein complex, conferring structural integrity and 
stability to the sarcolemma through connecting the muscle fiber cytoskeleton to the 
extracellular matrix, and protecting muscle fibers from mechanical stress during 
muscle contraction. Mutations in sarcoglycans coding genes cause primary limb-
girdle muscular dystrophy presented with early onset muscle weakness and associ-
ate with significant DCM [56]. Notably, mutations in the δ- sarcoglycan coding gene 
lead to DCM without involvement of obvious muscular dystrophy phenotypes [57].
Mutations in nuclear encoded mitochondrial genes such as TAZ and DNAJC19 
were also identified to cause DCM. TAZ encodes a mitochondrial localized 
Tafazzin protein that is predominantly expressed in cardiac and skeletal muscle. 
Tafazzin functions as a phospholipid transacylase that catalyzes the remodeling 
of cardiolipin that is required for oxidative phosphorylation. Mutations in the 
TAZ gene cause X-linked Barth syndrome and DCM, leading to premature death 
[58]. Mechanistically, mutations in TAZ result in Taffazin deficiency and cause 
mitochondrial dysfunction and impaired mitophagy and increased oxidative stress, 
leading to DCM [59].
3. Genetic testing
The advent of next-generation sequencing enables cost-effective genetic testing 
in familial DCM which can define the precise genetic cause of disease. Genetic 
testing can also help optimize risk stratification and assess prognostics of patients 
and their relatives. With the identification of a pathogenic mutation and early diag-
nostic certainty, clinical management of affect individuals could be tailored and 
patients’ survival can be improved. One best example is related to clinical practice 
of early intervention of DCM patients with LMNA mutations. LMNA-related DCM 
usually accompanied by significant conduction system disease, atrial fibrillation, 
ventricular tachycardia, and sudden cardiac death (SCD). Thus, LMNA mutations 
are often associated with a higher disease penetrance and more severe morbid-
ity and high mortality [60]. Studies in several different cohorts of DCM patients 
with LMNA mutations identified non-missense mutations, LVEF<45% and higher 
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AV blocker as significant risk factors for disease malignancy [61, 62]. Because of 
this well-determined genotype–phenotype knowledge, an actionable prognostic 
genotype–phenotype association, implementation of a lower threshold and earlier 
implantable cardioverter defibrillator (ICD) therapy than current guidelines 
recommend in patients with LMNA mutations, was demonstrated to significantly 
improve patient outcome and survival [63].
Based on the Genetic Testing Registry (https://www.ncbi.nlm.nih.gov/gtr/), 
there are from 40 to 80 genes included in the testing panels for most commercially 
available genetic testing for DCM. In familial DCM, the yield of genetic testing, 
resulting in identification of pathogenic mutations, can thus far reach up to 40%, 
in a comparable level to that of other inherited cardiac disorders such as HCM and 
long QT syndrome. The sensitivity of genetic testing is compromised partially due 
to that not all genes implicated in DCM are included in the gene panels for testing. 
This is especially the case for those identified from sporadic DCM cases or single 
family. Furthermore, limited by human genetics approaches that heavily rely on 
pedigree availability and candidate gene approaches, variants for more than half of 
familial DCM cases have not been identified yet. As technique advances in genet-
ics of cardiomyopathy, identification of the remaining genetic causes in inherited 
DCM cases and elucidation of the underlying pathogenic mechanisms leading to 
the phenotype are evolving rapidly. Targeted gene panels for genetic testing are 
increasing in an unprecedented scale. With further characterization and functional 
validation, the ever expanding gene panels of genetic testing promise to increase 
the rate of positive identification and provide individuals and families with a more 
comprehensive and conclusive genetic testing.
4. Genotype-targeted therapies
By directly targeting at specific pathogenic mutations causing DCM, genotype-
targeted genetic approaches have emerged as promising strategies for effective and 
individualized therapies to ameliorate disease phenotypes. To carry out genotype-
based therapy, many customized genetic strategies were explored. For examples: 
for loss-of-function mutations that cause reduced or insufficient protein levels, 
the straightforward gene replacement strategy can be employed. In this scenario, 
full-length or partial functional cDNA for corresponding mutated gene can be 
transferred to cardiac tissue to supplement the reduced gene dosage using appropri-
ate gene delivery approach. For mutations that cause dominant-negative effects on 
a particular gene, exon-skipping or trans-splicing approaches can be considered 
to remove or modify the mutant transcripts. For pathogenic mutations that cause 
other protein dysfunction, the highly efficient CRISPRA/Cas9 (Clustered regularly 
interspaced short palindromic repeats/CRISPR-associated endonuclease) system 
can be explored to directly correct the mutant variants. In addition, other genotype-
based therapeutic strategies such as manipulation of the downstream pathways 
evoked by specific DCM mutations were also explored. Below, we summarize 
several examples of gene-targeted therapeutic strategies that produced encouraging 
results in the treatment of DCM (Table 2), which hold the opportunities to ulti-
mately improve patient outcome in the future.
4.1 Dystrophin mutations-targeted gene therapies
Mutations in the dystrophin (DMD) gene cause muscular dystrophy patients and 
X-linked familial DCM in early childhood and patients often die of cardiac and respira-
tory failure [44]. Currently, there are no effective cures for DMD yet and management 
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of DMD mostly focuses on preserving the limited muscle strength and ameliorating 
disease symptoms [64]. Mechanistically, dystrophin protein deficiency due to DMD 
gene mutations is the primary cause of DMD and subsequent DCM and heart failure. 
And the disease severity is mostly correlated with the dystrophin protein level. Thus, 
a plausible treatment strategy would be to restore the expression level of dystrophin 
protein [44]. To cure this devastating disease, dystrophin gene-targeted therapeutic 
strategies such as gene replacement, exon skipping and CRISPRA/Cas9 genome editing 
techniques are mostly employed, which have shown encouraging results in restoration 
of dystrophin protein expression and recovery of dystrophin protein function in both 
animal models and clinical trials.
Gene replacement strategy involves delivering a functioning gene to replace or 
supplement the mutant gene to the target organ and cells to ease the disease pheno-
type caused by genetic mutation. This approach often utilizes the adeno-associated 
virus (AAV) as a vector to mediate gene transfection into the skeletal and cardiac 
muscle cells. However, as the dystrophin gene has 79 exons and its transcript is about 
14 Kb, its size is too large to fit in currently available gene construction vector for gene 
transfection. Alternatively, a mini- or micro- dystrophin gene coding for a function-
ally similar to dystrophin but smaller in size was thus used. The authors Wang and 
colleagues firstly defined the minimal functional region of the dystrophin protein, 
later referred as mini-dystrophin. The authors then packed this min-dystrophin gene 
into an AAV vector to mediate muscle transfection and demonstrated the effective-
ness of gene delivery and restoration of dystrophin gene function [65]. After this 
study, several other independent groups latter confirmed the effectiveness of a 
shortened albeit functional dystrophin gene replacement strategy mediated by the 
AAV gene delivery system in preservation of cardiac and skeletal muscle function and 
extending the lifespan in the dystrophic mice [66, 67]. Notably, further studies in ani-
mal models of muscular dystrophy and human patients detected certain immunologic 
responses to the shortened dystrophin peptide, which need to be carefully considered 
in future clinical application [68–70].
Exon skipping is an RNA-based splice-switching approach that causes cells to 
“skip” the exon containing the pathogenic variant, resultant in-frame transcripts 
that produce a shorter peptide, albeit still at least partially functional protein to 
ameliorate disease phenotypes. This approach was initially developed to mask 
the pathogenic mutations containing exon 51 using an antisense oligonucleotide 
(AON), resulting in genetic correction of the open reading frame of the DMD 
gene and partial restoration of dystrophin protein expression and improvement of 
muscle pathology and function [71–73]. These encouraging studies lead to at least 
two ongoing clinical trials to evaluate the efficacy and safety of this exon skipping 
approach targeting to the pathogenic exon 51 or 53 (NCT02255552, NCT02310906).
With the revolutionary development of the CRISPRA/Cas9 genome editing tech-
nologies that enable precise and efficient genetic modifications from single-nucleotide 
alternation, insertion of gene of interest to deletion of chromosomal regions, numer-
ous studies have demonstrated the feasibility and high efficiency of this technique in 
restoration dystrophin expression and function in skeletal and cardiac muscle, both 
in vitro and in vivo [74, 75]. For example, a recent study carried out by El Refaey and 
colleagues packaged SaCas9 (Cas9 from Staphylococcus aureus)/gRNA constructs into 
an AAV serotype rh74 and delivered it to the mdx/Utr+/− dystrophic mice through 
a retro-orbital approach [76]. The authors showed this CRIPRA-mediated genome 
editing strategy could efficiently excise the mutant exon 23 of dystrophin in the mice 
model, resulting in the restoration of the dystrophin protein expression and cardiac 
myofiber architecture, and significantly improved the cardiac contractility in vivo. 
A follow up study using this AAV-mediated CRISPR genome editing approach found 
that restored dystrophin expression and improved cardiac function were consistently 
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detected at up to 19 months [77]. Similarly, Hakim and colleagues modified the dose 
of AAV.SaCas9 and AAV-9.gRNA vector that directs Cas9 to introns of 22 and 23 and 
performed the AAV-9 CRISPRA gene therapy in the mdx mice that carry a nonsense 
mutation in exon 23 of the dystrophin gene [78, 79]. The authors found significantly 
increased dystrophin restoration and reduced fibrosis in both skeletal and cardiac 
muscle and improved muscle function and cardiac hemodynamics at up to 18 months.
4.2 LMNA mutations-tailored therapeutic strategy
A genetic approach referred as trans-splicing approach was initially carried 
out to correct LMNA mutations in the Lmna DelK32 knock-in mouse harboring 
a LMNA-related congenital muscular dystrophy mutation in the exon 1 [80, 81]. 
The Lmna DelK32/DelK32 mice exhibited severe muscular and cardiac defects and 
early premature death. The trans-splicing approach allows converting the targeted 
endogenous mutated pre-mRNA to a therapeutic pre–trans-spliced molecule 
containing the wildtype coding sequence, resulting in a processed mRNA tran-
script devoid of the exon harboring the pathogenic variant [82, 83]. To perform 
the trans-splicing rescue in the Lmna DelK32 knock-in mouse model, 5’-RNA 
pre-trans-splicing molecules containing the first five exons of Lmna and targeting 
intron 5 of Lmna pre-mRNA were firstly developed. After confirmed the induced 
trans-splicing events on endogenous Lmna mRNA in vitro, AAV mediated delivery 
system was then evaluated in vivo in the newborn mice. Similarly, trans-splicing 
events were successfully detected in both skeletal and heart muscle of mice up to 
50 days after AAV delivery. However, the tans-splicing occurring efficiency needs 
to be further improved to exert significant rescue effects on cardiac function and 
premature death.
To target at the LMNA pathogenic variants resulting in deficiency of the 
protein level, another strategy referred as stop codon readthrough was explored 
through inactivating the molecules participating in nonsense-mediated decay at 
the RNA level [84]. This approach applies to the scenario when pathogenic vari-
ants result in frameshifts and premature stops, subsequently leading to protein 
deficiency because of increased nonsense-mediated decay of mutant RNAs. 
PTC124, also known as ataluren, is a chemical compound that can selectively 
induce ribosomal readthrough of premature but not normal termination codons 
[85]. PTC124 was tested in iPSC-CMs derived from patients carrying different 
nonsense and frameshift mutations in the LMNA gene [85]. In one of the three 
frameshift mutants tested, administration of PTC124 significantly increased the 
translation of full-length LMNA protein and partially restored the protein func-
tion, as shown by reduced cardiomyocyte apoptosis and improved excitation-
contraction coupling [84].
4.3 TTN truncating variants-targeted gene therapy
While the pathogenicity of TTN missense mutations to DCM remains largely 
undetermined, TTN truncating variants (TTNtvs) are the most common cause to 
DCM. To date, experimental evidence generated largely from rodent animal mod-
els, human induced pluripotent stem cell-derived cardiomyocyte, and patient tis-
sues mostly support the mechanism of titin protein haploinsufficiency. Correction 
of the titin protein deficiency by using traditional viral-mediated gene replacement 
strategy to increase the expression of titin protein, just as that has been successfully 
employed to restore the dystrophin deficiency, however, is challenging. Because the 
TTN gene spans 294 Kb of genomic region and its spliced transcript is more than 
100 Kb, a size that is way bigger than any currently available cargo capacity for AAV 
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mediated gene transfection. Alternatively, exon skipping, a genetic approach that 
had been initially employed to treat the DMD, through using an AON to mask the 
pathogenic mutations containing exon 51 or 53 and restoration of DMD phenotype 
[72], as aforementioned, was explored to treat TTNtvs related DCM. Notably, this 
strategy had been also successfully utilized for treating Mybpc3 mutations caused 
HCM in a knock-in mouse model [86].
To employ exon skipping strategy for treating TTNtvs caused DCM, Gramlich 
and colleagues targeted to the Ser14450fsX4 variant located in the exon 326 identi-
fied in a DCM patient that caused autosomal-dominant truncating frameshift 
mutation [87]. They used an AON-mediated exon skipping approach to remove 
the exon 326 in both patient cardiomyocytes in vitro and mouse heart in vivo. In 
vitro, skipping of the exon 326 containing the Ser14450fsX4 pathogenic variant 
restored the impaired myofibril assembly and stabilized its structural integrity and 
normalized expression of sarcomeric protein in the patient-specific cardiomyocytes 
derived from induced pluripotent stem cells (iPSC-CMs) model. Furthermore, in 
the corresponding Ttn knock-in mice model, skipping of the exon 326 significantly 
improved sarcomere formation and contractile function and prevented subsequent 
development of DCM phenotype. These results provide strong evidence to support 
that the RNA-based exon skipping strategy could be a potential treatment option 
for DCM caused by gene variants that are otherwise technically difficult to be 
delivered due to size limitation for gene replacement therapy.
4.4 Genotype-targeted therapies for other DCM genes
Mutations in the δ- sarcoglycan coding gene (SGCD) can lead to DCM without 
obvious involvement of skeletal muscle disorders [57]. The gene replacement 
strategy was firstly applied in the treatment of DCM caused by a deletion mutation 
in the Sgcd gene that disrupted the dystrophin-associated glycoprotein complex in a 
hamster model [88]. The authors Kawada and colleague constructed a recombinant 
AAV vector containing the full-length cDNA of Sgcd gene driven under the cardiac 
specific expression promoter of CMV and intramurally injected it to the Sgcd muta-
tion induced DCM model in the hamster. They detected robust expression of the 
Sgcd gene and other types of sarcoglycans as well in the transfected myocardium. 
The restored expression of Sgcd and other sarcoglycans normalized the diameter 
of transduced cardiomyocytes, improved the contractile function and ultimately 
prolonged the life span of the animals harboring the Sgcd gene mutation. This study 
provides one of the earliest evidence to employ gene replacement strategy to treat 
DCM caused by a specific gene mutation with efficient and sustained transfection 
capability.
An earlier version of genome editing technique referred as transcription activator-
affected nuclease (TALEN) was explored to directly correct the PLN R14del mutation 
that is associated with high risk for malignant ventricular arrhythmias and end-stage 
heart failure in DCM patient carriers [89]. The authors Karakikes and colleague 
firstly derived iPSC-CMs from a DCM patient harboring the PLN R14del mutation, 
followed by detailed phenotypic characterization of this iPSC-CMs model. Next, 
the authors made the effort to correct the PLN R14del mutation in the iPSC-CMs 
model using TALEN gene editing strategy. This approach successfully corrected 
the R14del mutation and attenuated the R14del-associated disease phenotypes in 
the iPSC-CMs model. Furthermore, the authors engineered an AAV6 vector that 
enabled knock-down the endogenous PLN, while simultaneously overexpress a 
codon-optimized PLN, to effectively reverse the disease phenotype in the iPSC-CMs 
model as well. Thus, this study provides another successful example to using genome 
editing approach to directly target at the pathogenic mutations associated with DCM 
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to achieve therapeutic benefit. Notably, while it provides evidence to support the 
effectiveness of genome editing technique to correct pathogenic variants causing 
DCM in vitro, germline correction of embryos harboring DCM variants had not been 
reported yet.
5. Conclusions
The ultimate goal of elucidating genetic basis for DCM is for early disease 
diagnosis, early disease intervention and treatment. To date, pathogenic mutations 
in more than 50 genes are associated with DCM. However, these mutations can only 
explain about 40–50% of familial DCM cases, and the genetic architecture of DCM 
still remains incompletely understood. Future research directions rely on technique 
advances for identification of the remaining up to 60% of genetic causes in familial 
DCM cases. After identifying the genetic causes, functional characterization and 
validation studies are needed to confirm the pathogenic variants. Extensive stud-
ies on delineation of genotype–phenotype relationships are necessary to address 
currently unmet issues for translational research. Further dissecting genetic 
pathways linked to DCM and elucidating the pathogenic mechanisms leading to the 
phenotype can provide valuable insights into the understanding of disease patho-
physiology, laying solid foundation for future development of groundbreaking 
therapeutics.
Gene-based therapies, such as gene replacement, exon skipping and recent evo-
lutionarily developed CRISPRA/Cas9 based genome-editing techniques that directly 
target at the underlying genetic mutations responsible for the DCM disease pro-
gression, have led to several clinical trials which have produced promising results. 
Thus, the last decade has witnessed encouraging advances in the development of 
genotype-targeted, personalized therapies. While the progress is promising, several 
technical issues need to be thoroughly assessed before implementation in clinical 
practice. For example, current gene delivery system mostly adapt the AAV system 
because of its many advantages such as long term transgene expression and choice 
of appropriate serotype for heart enriched expression. One primary limitation for 
this system, however, is that there exists certain level of anti-AAV antibodies in 
general human population causing the immunogenicity issue which can potentially 
lead to development of myocarditis [70, 90–92]. While the efficiency for exogenous 
delivery of preprocessed RNAs or oligonucleotides for trans-splicing or exon skip-
ping needs to be further improved, a major concern of off-target issue needs to be 
seriously addressed for the highly efficient AAV9 mediated CRISPR/Cas9 genome 
editing system. Novel approaches are desirable to comprehensively evaluate any 
potential off-target mutagenesis in the heart and other tissues for future clinical 
application.
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